Hypertension:儿童视网膜血管直径与血压变化

2020-06-30 网络 网络

视网膜小动脉变窄可预测收缩压的演变。反过来,较高的初始收缩压和舒张压与随后发生的微血管损伤有关。该研究的结果为儿童血压与微血管健康之间的双变量时间关系提供了良好的证据。

全球儿童期高血压(BP)的发病率正在上升,并与儿童的亚临床血管损伤有关。目前缺乏关于儿童微血管改变与高血压发展相关的纵向数据。近日,心血管权威杂志Hypertension上发表了一篇研究文章,研究人员旨在分析4岁以上儿童视网膜中央小动脉(CRAE)和静脉(CRVE)直径与高BP发生发展之间的关系。

2014年,研究人员采用标准化方案对391名6至8岁的儿童进行了BP和视网膜血管直径的筛查,并使用视网膜血管分析仪进行视网膜血管分析,以确定CRAE和视网膜中央小静脉的数据。在2018年的后续随访中,研究人员使用相同的标准化方案评估了262名儿童的所有参数。

在随访期间,收缩压和舒张压显著增加(分别为Δ3.965±8.25和1.733±7.63 mmHg),而CRAE降低了Δ−6.325±8.55 µm,而视网膜中央静脉数据无明显变化(Δ−0.163±7.94um)。基线时CRAE较窄的儿童在四年后出现较高的收缩压(每降低10 µm的β[95%CI]为0.78 [0.170–1.398] mmHg,P=0.012)。基线时收缩压或舒张压升高的儿童的CRAE较窄(每升高1mmHg的β[95%CI]为-0.154 [-0.294至-0.014] µm,P=0.031和每升高1mmHg的β[95%CI]为-0.02[-0.344至-0.057] µm,P=0.006)。

由此可见,视网膜小动脉变窄可预测收缩压的演变。反过来,较高的初始收缩压和舒张压与随后发生的微血管损伤有关。该研究的结果为儿童血压与微血管健康之间的双变量时间关系提供了良好的证据。

原始出处:

Giulia Lona.et al.Retinal Vessel Diameters and Blood Pressure Progression in Children.Hypertension.2020.https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.120.14695

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2039201, encodeId=834220392010a, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jan 01 01:09:14 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709695, encodeId=bfdf1e0969539, content=<a href='/topic/show?id=4cc58893ea0' target=_blank style='color:#2F92EE;'>#血压变化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88937, encryptionId=4cc58893ea0, topicName=血压变化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1b531772449, createdName=ms1467340776200723, createdTime=Tue Oct 20 16:09:14 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728584, encodeId=81b71e2858447, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Oct 05 20:09:14 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270248, encodeId=761f12e02489a, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Jul 02 04:09:14 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501483, encodeId=471f1501483cb, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Jul 02 04:09:14 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800573, encodeId=f1a28005e303, content=很实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=46055325267, createdName=148b929fm56(暂无昵称), createdTime=Tue Jun 30 13:23:14 CST 2020, time=2020-06-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2039201, encodeId=834220392010a, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jan 01 01:09:14 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709695, encodeId=bfdf1e0969539, content=<a href='/topic/show?id=4cc58893ea0' target=_blank style='color:#2F92EE;'>#血压变化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88937, encryptionId=4cc58893ea0, topicName=血压变化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1b531772449, createdName=ms1467340776200723, createdTime=Tue Oct 20 16:09:14 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728584, encodeId=81b71e2858447, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Oct 05 20:09:14 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270248, encodeId=761f12e02489a, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Jul 02 04:09:14 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501483, encodeId=471f1501483cb, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Jul 02 04:09:14 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800573, encodeId=f1a28005e303, content=很实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=46055325267, createdName=148b929fm56(暂无昵称), createdTime=Tue Jun 30 13:23:14 CST 2020, time=2020-06-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2039201, encodeId=834220392010a, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jan 01 01:09:14 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709695, encodeId=bfdf1e0969539, content=<a href='/topic/show?id=4cc58893ea0' target=_blank style='color:#2F92EE;'>#血压变化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88937, encryptionId=4cc58893ea0, topicName=血压变化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1b531772449, createdName=ms1467340776200723, createdTime=Tue Oct 20 16:09:14 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728584, encodeId=81b71e2858447, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Oct 05 20:09:14 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270248, encodeId=761f12e02489a, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Jul 02 04:09:14 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501483, encodeId=471f1501483cb, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Jul 02 04:09:14 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800573, encodeId=f1a28005e303, content=很实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=46055325267, createdName=148b929fm56(暂无昵称), createdTime=Tue Jun 30 13:23:14 CST 2020, time=2020-06-30, status=1, ipAttribution=)]
    2020-10-05 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=2039201, encodeId=834220392010a, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jan 01 01:09:14 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709695, encodeId=bfdf1e0969539, content=<a href='/topic/show?id=4cc58893ea0' target=_blank style='color:#2F92EE;'>#血压变化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88937, encryptionId=4cc58893ea0, topicName=血压变化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1b531772449, createdName=ms1467340776200723, createdTime=Tue Oct 20 16:09:14 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728584, encodeId=81b71e2858447, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Oct 05 20:09:14 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270248, encodeId=761f12e02489a, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Jul 02 04:09:14 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501483, encodeId=471f1501483cb, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Jul 02 04:09:14 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800573, encodeId=f1a28005e303, content=很实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=46055325267, createdName=148b929fm56(暂无昵称), createdTime=Tue Jun 30 13:23:14 CST 2020, time=2020-06-30, status=1, ipAttribution=)]
    2020-07-02 zutt
  5. [GetPortalCommentsPageByObjectIdResponse(id=2039201, encodeId=834220392010a, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jan 01 01:09:14 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709695, encodeId=bfdf1e0969539, content=<a href='/topic/show?id=4cc58893ea0' target=_blank style='color:#2F92EE;'>#血压变化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88937, encryptionId=4cc58893ea0, topicName=血压变化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1b531772449, createdName=ms1467340776200723, createdTime=Tue Oct 20 16:09:14 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728584, encodeId=81b71e2858447, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Oct 05 20:09:14 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270248, encodeId=761f12e02489a, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Jul 02 04:09:14 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501483, encodeId=471f1501483cb, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Jul 02 04:09:14 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800573, encodeId=f1a28005e303, content=很实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=46055325267, createdName=148b929fm56(暂无昵称), createdTime=Tue Jun 30 13:23:14 CST 2020, time=2020-06-30, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2039201, encodeId=834220392010a, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jan 01 01:09:14 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709695, encodeId=bfdf1e0969539, content=<a href='/topic/show?id=4cc58893ea0' target=_blank style='color:#2F92EE;'>#血压变化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88937, encryptionId=4cc58893ea0, topicName=血压变化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1b531772449, createdName=ms1467340776200723, createdTime=Tue Oct 20 16:09:14 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728584, encodeId=81b71e2858447, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Oct 05 20:09:14 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270248, encodeId=761f12e02489a, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Jul 02 04:09:14 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501483, encodeId=471f1501483cb, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Jul 02 04:09:14 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800573, encodeId=f1a28005e303, content=很实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=46055325267, createdName=148b929fm56(暂无昵称), createdTime=Tue Jun 30 13:23:14 CST 2020, time=2020-06-30, status=1, ipAttribution=)]
    2020-06-30 148b929fm56(暂无昵称)

    很实用

    0

相关资讯

JAHA: 超重儿童心脏较大,主要是因为肌肉多!荷兰研究

近日发表的一项荷兰队列研究表明,在儿童时期,体重指数越高,心室更大,包括左心室和右心室。

Nat Med:被选为封面:领域影响**,被下载32万次,龚四堂/张康/唐金陵/夏慧敏的这个成果到底回答了什么问题?

直肠拭子测试可能比鼻咽拭子测试在判断治疗效果和确定检疫终止时机方面更有用。

Int J Pediatr Otorhinolaryngol:听力损伤儿童的感觉处理障碍

最近,有研究人员探究了听力损伤和正常听力儿童的感觉处理差异,以及影响感觉处理障碍的因素(SPD)。

Brit J Heamatol:免疫性血小板减少症儿童和青少年疲劳状况

在ITP儿童和青少年中,疲劳很常见,即使没有出血症状,也可以从ITP指导的治疗中受益。

Int J Pediatr Otorhinolaryngol:单边耳聋儿童的治疗挑战和临床特征

儿童单侧耳聋(SSD)的临床意义历来不被患者和医疗机构所重视,尽管有大量的文献报道产生了神经认知、语言、学习和功能障碍。传统扩增治疗的特点是结果多样,而且随访经常丢失。

Eur Arch Otorhinolaryngol:新的SMS系统在耳蜗前庭异常中的应用

最近,有研究人员呈现和分析了9名III型前庭耳蜗畸形儿童的放射学发现、手术发现、移植前后言语和听力结果情况。